Beijing Tong Ren Tang Chinese Medicine Co (HKSE:03613) EBIT: HK$510 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:03613 Beijing Tong Ren Tang Chinese Medicine Co Ltd HKSE:03613
89 GF Score
Price HK$6.90
GF Value HK$9.64
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Beijing Tong Ren Tang Chinese Medicine Co EBIT?

Beijing Tong Ren Tang Chinese Medicine Co HKSE:03613 -1.85% 89 EBIT is HK$510 Mil as of Dec. 2025. GuruFocus rates HKSE:03613 with a GF Score™ of 89/100 and a GF Value™ of HK$9.64 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Beijing Tong Ren Tang Chinese Medicine Co's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was HK$217 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$510 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Beijing Tong Ren Tang Chinese Medicine Co's annualized ROC % for the quarter that ended in Dec. 2025 was 17.71%. Beijing Tong Ren Tang Chinese Medicine Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 20.51%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Beijing Tong Ren Tang Chinese Medicine Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 13.42%.

Beijing Tong Ren Tang Chinese Medicine Co  (HKSE:03613) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Beijing Tong Ren Tang Chinese Medicine Co's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=527.716 * ( 1 - 20.51% )/( (2447.12 + 2290.541)/ 2 )
=419.4814484/2368.8305
=17.71 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4534.467 - 81.802 - ( 2005.545 - max(0, 215.978 - 3924.9+2005.545))
=2447.12

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4660.738 - 90.973 - ( 2279.224 - max(0, 206.848 - 4064.756+2279.224))
=2290.541

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Beijing Tong Ren Tang Chinese Medicine Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=434.598/( ( (432.594 + max(1747.203, 0)) + (449.829 + max(1608.302, 0)) )/ 2 )
=434.598/( ( 2179.797 + 2058.131 )/ 2 )
=434.598/2118.964
=20.51 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(408.849 + 1457.297 + 38.754) - (81.802 + 0 + 75.895)
=1747.203

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(394.87 + 1341.633 + 26.349) - (90.973 + 0 + 63.577)
=1608.302

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Beijing Tong Ren Tang Chinese Medicine Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=510.349/3804.277
=13.42 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beijing Tong Ren Tang Chinese Medicine Co EBIT Related Terms

Beijing Tong Ren Tang Chinese Medicine Co EBIT Historical Data

* Premium members only.

The historical data trend for Beijing Tong Ren Tang Chinese Medicine Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beijing Tong Ren Tang Chinese Medicine Co EBIT Chart

Beijing Tong Ren Tang Chinese Medicine Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 783.10 830.62 693.77 636.25 510.35

Beijing Tong Ren Tang Chinese Medicine Co Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 337.13 286.86 349.39 293.05 217.30

HKSE:03613 vs ZTS, UTHR: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Beijing Tong Ren Tang Chinese Medicine Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Beijing Tong Ren Tang Chinese Medicine Co EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Beijing Tong Ren Tang Chinese Medicine Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Beijing Tong Ren Tang Chinese Medicine Co's EV-to-EBIT falls into.


HKSE:03613
89GF Score
Beijing Tong Ren Tang Chinese Medicine Co Ltd HKSE:03613
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beijing Tong Ren Tang Chinese Medicine Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$510 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of HK$510 Mil mean?
Beijing Tong Ren Tang Chinese Medicine Co (HKSE:03613) has a EBIT of HK$510 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Beijing Tong Ren Tang Chinese Medicine Co.
Is Beijing Tong Ren Tang Chinese Medicine Co's EBIT too high?
Beijing Tong Ren Tang Chinese Medicine Co's current EBIT is HK$510 Mil. Overall, Beijing Tong Ren Tang Chinese Medicine Co has a GF Score™ of 89/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Beijing Tong Ren Tang Chinese Medicine Co's EBIT compare to ZTS and UTHR?
Beijing Tong Ren Tang Chinese Medicine Co's EBIT of HK$510 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Beijing Tong Ren Tang Chinese Medicine Co. Beijing Tong Ren Tang Chinese Medicine Co's current EBIT is HK$510 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Tong Ren Tang Chinese Medicine Co stock overvalued right now?
Based on GuruFocus' analysis, Beijing Tong Ren Tang Chinese Medicine Co (HKSE:03613) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$9.64, compared to a current price of HK$6.90 — trading 28.4% below its estimated fair value. The current EBIT is HK$510 Mil. Beijing Tong Ren Tang Chinese Medicine Co's overall GF Score™ is 89/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Beijing Tong Ren Tang Chinese Medicine Co (HKSE:03613), the current EBIT is HK$510 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Beijing Tong Ren Tang Chinese Medicine Co (HKSE:03613) Overvalued in 2026?

Based on GuruFocus' analysis, Beijing Tong Ren Tang Chinese Medicine Co stock appears to be undervalued. The current stock price of HK$6.90 is trading 28.4% below its estimated GF Value™ of HK$9.64. GuruFocus considers Beijing Tong Ren Tang Chinese Medicine Co to be Modestly Undervalued.

Key valuation signals for HKSE:03613:

  • EBIT: HK$510 Mil
  • GF Value™: HK$9.64 vs. price of HK$6.90 (28.4% below fair value)
  • GF Score™: 89/100 with 3 warning signs

No single metric tells the full story. See the HKSE:03613 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Beijing Tong Ren Tang Chinese Medicine Co Business Description

Other Exchanges TQR:Germany
Address Convention Plaza, 1 Harbour Road, Room 1405-1409, Office Tower, Wanchai, Hong Kong, HKG
Beijing Tong Ren Tang Chinese Medicine Co Ltd is a pharmaceutical retailer that specializes in Chinese medicine operating in three segments; Hong Kong includes the sale of Chinese medicine products and healthcare products and the provision of Chinese medical consultation and treatments through retail and wholesale of Chinese medicine products and healthcare products; Chinese Mainland (PRC, but excluding Hong Kong, Macao, and Taiwan) includes wholesale of healthcare products in Chinese Mainland and the sole distributor of Tong Ren Tang branded products of Tong Ren Tang Technologies and Tong Ren Tang Ltd; and Overseas includes retail and wholesale of Chinese medicine products and healthcare products and provision of Chinese medical consultation and treatments.
89GF Score

Get the complete analysis for HKSE:03613

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$6.90
Price
HK$9.64
GF Value